


Medicines from plants

- Fresh plants or their parts (Myrtilli fructus recens)
- Dried plants or their parts = drugs
- Isolates from fresh plants and drugs (chemically defined compounds)

Medicines from animals (mostly isolates)

Medicines from marine organisms (Plexaura homomala - prostaglandins)


Medicines obtained by biotechnology (enzymes, hormones, cytokines, monoclonal antibodies, inhibitors of tyrosinkinase...)




Key importance for quality has a technological process for manufacturing

Valerianae radix water = hydrophilic compounds without sedative effect chloroform = sedative valepotriates

Pharmaceutical and medical research intensively make a point of identification of main active content compound and its quantification in final medicinal formulation.






PHYTOPHARMACEUTICALS

No law-defined definition for phytopharmacuticals.


Germany:

- Medicines exclusively or predominantly composed from plants, palt parts, plant content compounds (generaly drugs with nonorganised structure as it is resine or essential oil) if these are not listed in homeopatic anad anthroposophic groups of compounds.
- Medicines of plant origin including plant isolates (chemical individua) with defined structure.



NATURAL MEDICINES AND MATERIAL FOR THEIR PREPARATION

- MEDICINAL PLANT such as plant, which is used whole or its parts in different forms directly for treatment of diseases, or as a material for medicaments preparation. Fresh medicinal plants, their parts or products are used for therapy exceptionally.
- DRUG dried, alternatively conserved by different way, modified or un-modified plant (animal), or its organ or part, alternatively its product, which serves for manufacturing medicaments or technically important compounds, or directly used for therapeutical, technical, or other purposes.
- PARTES USUALES collected and used parts of plants, in which the biologically active compound is in the highest amount.



DRUG DIVISION

ACCORDING TO THE ORIGIN

plant (vegetabile) animal

ACCODING TO THE STRUCTURE

- Drugs with organized structure majority of plant drugs and partly animal drugs, showing cellular constitution from one cell to set of tissues in constant order: Lupulinum, Lichen islandicus, Belladonnae radix
- Amorphous drugs

different plant and animal drugs, without cellular organization. Are derived as: physiologic products: Resina mastix,

pathologic products: Balsamum peruvianum


products obtained from raw material by destillation (Menthae etheroleum), melting (Adeps suillus), stamping (Olivae oleum), extraction (Chrysarobinum), thickening (Liquiritiae succus)

ACCORDING TO THE USAGE

- Drugs therapeutical (used for medicaments preparation or for isolation of effective compounds)
- Drugs utilitarian (manufacturing of colors, tannery, food industry, cosmetics)

CONTENT COMPOUNDS

- Compounds effective, active principles, main compounds (pharmacodynamics)
- Co-effectors, affecting main compounds (pharmacokinetics) .
- Dietetics (sugars, fats, proteins) .
- Adjuvants (starches, gums)
- Accompanying compounds (lignine, pigments, Ca oxalate) .
- Balast compounds .






- Maceration in water, pressing, pasteurization, uperization
- Containing hydrophilic compounds (sugars, vitamins, amino acids, organic acids...)
- Do not contain strongly effective compounds
- Freely distributed, self-treatment

•

HOMEOPATIC TICKTURES

- Maceration in 90% EtOH, pressing \longrightarrow URTINCTURE (allopatic)
 - Preparation according to HAB and Ph.Eur.
 - for example Nux vomica Φ = D1 equivalent Strychni tinctura
- · dilution, potentiation, dynamisation, infinitesimal doses




INSTANT TEAS

Extracta aquosa sicca = granulations (vacuum, lyophilisation)

Extracta aquosa spissa seu fluida = paste

Additional compounds - lipophilic compounds (essential oil)


Most often preparations for treatment of stomach disorders



4. Cannot be used

1-4: Qualitative criterions according to ČL 2002; ON

Back to nature: Plant medicines are not almighty and are not harmless!!



ČL 2002 – Suppl. 2003


EXTRACTS – extract from drug (macerate, percolate) with more or less removed extraction medium.

Extracts can be divided:

- **Liquid** (liquid extracts and tinctures) drug : EtOH = 1:5; 1:10; *Extractum fluidum* (extractive compounds from 1 portion of drug are contained in 1, maximally 2 portions of extract.
- Semi-liquid (thick extracts) *Extractum spissum* (original, non-modified extracts, containing 15 25 % residual solvents.
- Solid (dried extracts) Extractum siccum (with max. content of 5 % of residual solvents).

Standardized extracts – are modified to contain required of compounds with known therapeutic potential; standardization is carried out using inert compounds or by mixing different extracts (different batch). **Quantified extracts** – corrected to required content of desired compounds.

 Other extracts – are defined especially by manufacturing procedure (characteristics of plant or animal drug used for extraction, type of solvent and extraction conditioning) and its properties.




- · Changes of effective compounds in GIT
- · Specifity of effective compounds
- Kinetics of effective compounds
- Dosage and tolerance
- Accumulation of effective compounds in organism
- Synergism or antagonism
- Status of patient

FOLK MEDICINE, SELF-TREATMENT

Risks of ignorance

- Impossibility of correct diagnose?
- Choice of medicament?
- Dosage?
- Period of therapy?
- Knowledge of practical experience



REGISTRATION IN CZECH REPUBLIC - STATE INSTITUTE FOR DRUG CONTROL



REQUEST FOR REGISTRATION AS LARGE SCALE MANUFACTURED DRUG

1. BASIC DATA Name of preparation Drug form Name and address of manufacturer, applicant Company responsible for marketing Datum, signature

2. BASIC CHARACTERISTICS Composition (Czech, Latin, INN of effective compounds and adjuvants) Pharmacologic data (indication, contraindication, dosage, exceptional data – pregnancy, breast-feeding...) Pharmaceutical data (description of preparation, type of package, size of package, expiration, storage)

- 3. PHARMACEUTIC-TECHNOLOGIC DOCUMENTS quantitative composition of medicament manufacturing description drug specification according to Eur. Ph. Or branch norm determination of pesticide residues
- CONTROL OF FINAL PREPARATION Assays and procedures for phys.-chem. methods according to Eur. Ph. Microbial assays Biological assay



REQUEST FOR REGISTRATION AS LARGE SCALE MANUFACTURED DRUG

5. STABILITY STUDIES Description Possible products of decomposition Results according to different conditions of keeping and storage

- 6. TOXIKOLOGIC AND PHARMACOLOGIC DOCKUMENTATION
- 7. CLINICAL DOCUMENTATION
- 8. CERTIFICATION ABOUT REGISTRATION
- 9. CERTIFICATION OF MANUFACTURER ABOUT GMP

10. MISCELANEOUS Original package including leaflet Samples (including referential standards) for 3 full analyses

CLINICAL ASSAYS OF PHYTOPHARMACEUTICALS

- All rules for clinical pharmacology are valid:
- 1. Definition of disease and symptoms
- 2. The matter of clinical assay, the time limits
- 3. To know the exact composition of phytopharmaceutic, chemical structure of compound, presumed therapeutic effect
- 4. To determine if the test will be individual, with placebo, or with known therapeutic
- 6. To determine daily doses, time of administration with regard to possible effect of feeding
- 7. Number and selection of patients (ambulant hospitalized / acute chronic
- 8. Type of study (opened, simply or double blindened)
- 9. Definitions of criterions for effect evaluation (value of blood pressure, level of serum lipoproteins...)
- 10. The way of analysis of acquired results, definition of criterions of effectiveness
- 11. Exclusion of extra pharmacological effects
- 12. To monitor the time of start and duration of effect
- 13. Topic preparations dermatotropic activity

CLINICAL ASSAYS

- · For all newly used drugs
- · For plant species till present not used for medicals preparation
- · Drug with unknown content compounds
- Known drug till present does not used as medicinal
- · New indications of known phytopharmaceuticals
- Foreign drugs non-registered in Czech Republic

APPROVAL OF NEW MEDICINES

New drug is important factor, which can affect improvment of health status and quality of life, and possibly to safe the life. Therefore the attention is laid also on duration of approval process to imply new drug on market. This is defined as overall number of calendar days from application to issue the approval. From the monitoring of duration of approval process for 70 new chemical entities, which were under approval process 1995-1999 can be deduced: median of duration of approval process in Australia (43 new drugs) was 25,3 of month, in Canada (70) 29,4 of months, in Sweden (48) 27,3 months, Great Britain (54) 11,7 of months and in USA (57 ne drugs) 25,5 of months. Duration of approval process is not significantly affected by therapeutic classification, number of required and additional information or datum of application.

Pieterson E.A.: J Clin Pharmacol, 32, 2002 s. 889